48-week RESIST data confirms TPV benefit.

摘要

Findings from the Randomized Evaluation of Strategic Intervention in Multi-Drug ResiStant Patients with Tipranavir (RESIST) studies have shown that the new protease inhibitor (PI) tipranavir (TPV) continues to provide potent activity against HIV in patients with substantial treatment experience after 48 weeks of treatment. The data were presented at the 10th European AIDS Conference, held November 17-20, 2005, in Dublin.Tipranavir is the latest PI to be approved in Europe and the United States, where it is licensed for use in patients who have experienced failure of previous Pi-based regimens. The drug's approvals were based on 24-week data from the phase 3 RESIST-1 and RESIST-2 studies, showing that patients taking TPV had better outcomes than those in a comparator group.